Summary Cancer chemotherapy interacts with cell proliferation, but data on the relationship between cancer cell replication and the effect of adjuvant chemotherapy are scarce. We have investigated the S-phase fractions of the primary tumour from premenopausal breast cancer patients who participated in a randomised trial comparing 12 cycles of polychemotherapy (CMF) with post-operative radiotherapy. DNA flow cytometry was performed on frozen tissues from 208 primary breast carcinomas, of which the S-phase fraction was estimated in 176 cases. There was a significantly higher benefit from CMF among patients with a high S-phase fraction (P = 0.0033). The relative risk of distant recurrence or death in the chemotherapy group as compared with the radiotherapy group was 0.19 for patients whose tumours had an S-phase fraction of 10% or over (95% CI 0.07-0.51) and 1.55 (0.88-2.73) for patients whose tumours showed lower S-phase levels. The interaction was still significant in multivariate analysis (P = 0.0057), including lymph node metastases, tumour size and oestrogen receptor content. We conclude that the benefit from adjuvant chemotherapy compared with radiotherapy is largely confined to patients with highly proliferative tumours.
It has become evident that patients with early breast cancer benefit from adjuvant systemic therapy (Early Breast Cancer Trialists' Collaborative Group, 1992) . Combination chemotherapy given at the time of primary treatment can reduce the risk of death from breast cancer by 25% in young women. On the other hand, most patients will either remain disease free without or relapse despite such treatment. An increasing number of biological factors have been demonstrated to correlate with prognosis of patients with breast cancer, but it is still difficult to predict accurately the response to treatment.
Cancer chemotherapy interacts with cell proliferation. Studies concerning treatment of metastatic breast cancer and preoperative chemotherapy have shown that patients with highly proliferating breast tumours are more likely to respond to cytotoxic therapy (Sulkes et al., 1979; O'Reilly et al., 1992; Remvikos et al., 1992; Spyratos et al., 1992) . Data on the relationship between the proliferating activity of the primary tumour and the effect of adjuvant chemotherapy in patients with breast cancer are scarce and apparently conflicting (Bonadonna et al., 1986; Hedley et al., 1987; O'Reilly et al., 1990; Witzig et al., 1993) .
We have therefore analysed retrospectively by DNA flow cytometry the S-phase fractions of frozen tumour specimens from premenopausal breast cancer patients who participated in a large randomised trial comparing 12 cycles of adjuvant polychemotherapy with post-operative radiotherapy.
Patients and methods
In 1976 the Stockholm Breast Cancer Group initiated a trial to compare post-operative radiotherapy with adjuvant chemotherapy (Rutqvist et al., 1989 and 7%. For the estimation of S-phase fraction (SPF) a planimetric method was used, assuming the S-compartment to have rectangular distribution (Baisch et al., 1975) . In order to minimise the influence of overlapping populations in the DNA histogram, the height of the rectangle was estimated from a manually selected area that was judged as representative. Although the majority of the histograms showed only slight background debris to the right of the G2/M peak, background correction was performed according to a baseline model. By this correction the mean number of histogram events per channel in an interval to the right of the G2/M peak was subtracted from that in the S-phase interval. The SPF was estimated in 176 of the tumours (85%) and ranged between 0.5% and 35%. The mean S-phase value was 7.1% and the median was 5.9%.
Statistical methods
The risk of distant recurrence or death in relation to different variables or interactions between variables was estimated and tested using Cox's proportional hazards model (Cox, 1972) . The statistical significance of the interaction between S-phase fraction and treatment was evaluated by treating the S-phase fraction as a continuous variable in the Cox model, in that the prespecified S-phase categories, <5%, 5-10% and > 10%, were coded 1, 2 and 3 respectively. To adjust for the potentially confounding effects of other variables, e.g. tumour stage and oestrogen receptor content, we performed additional Cox analyses in which the model was stratified according to the other variables. The product-limit method was used for estimation of cumulative probabilities of distant disease-free survival (Kaplan & Meier, 1958) .
Results
Characteristics of the material are shown in Table I . A high S-phase fraction was significantly associated with low oestrogen receptor content (P<0.0001) and DNA aneuploidy (P<0.0001), while subgroups categorised by tumour stage showed no significant difference according to SPF (P= 0.18). Using Cox's proportional hazards model, there was a clearly significant interaction between S-phase fraction and treatment effect (Table II) . The relative risk of distant recurrence or death in the chemotherapy group as compared with the radiotherapy group was 0.19 for patients whose tumours had an S-phase fraction of 10% and over (95% confidence interval 0.07-0.51) and 1.55 (0.88-2.73) for patients whose tumours had an S-phase fraction less than 10%. For patients with highly proliferating tumours the estimated distant disease-free survival rate at 5 years was 68% in the CMF group, while it was 30% in the radiotherapy group ( Figure  1 ). Similar results were obtained when restricting the analysis to survival (data not shown).
The correlation between S-phase fraction and the outcome difference between the two treatments was still significant in a stratified Cox analysis, taking into account possible interactons between treatment and the number of positive lymph nodes, tumour size and oestrogen receptor (ER) content (Table III) (100) 'Number of patients (%). bData on ER content were missing in three cases. significant (P = 0.0030). A similar trend was seen for the ER-positive subgroup.
In the DNA diploid and the DNA aneuploid subgroups, there was no significant difference in outcome between patients receiving chemotherapy and radiotherapy (Table  IV) . The relative risk comparing the two treatments was not significantly different for patients having DNA diploid or aneuploid tumours (P = 0.63). If the tumours were categorised into DNA hypodiploids (11%) and others, we found a significant interaction with treatment effect (P = 0.00 12). Among the patients with DNA hypodiploid tumours, all eight patients receiving radiotherapy relapsed or died during the follow-up period compared with 5 of 14 patients receiving cytotoxic therapy. Of the DNA hypodiploid tumours with assessable S-phase fraction, most tumours (72%) showed a level of 10% or higher.
Discussion
The results of the present study suggest that the benefit from adjuvant chemotherapy in premenopausal breast cancer patients is largely confined to those with highly proliferative primary tumours. Previously reported evidence for this is scarce for adjuvant chemotherapy, but the presumption that rapidly proliferating tumours are more chemosensitive than others is supported by studies concerning preoperative chemotherapy and the treatment of metastatic disease. Sulkes et al. (1979) analysed the response to chemotherapy in 25 women with disseminated breast cancers in relation to the proliferative activity estimated as the thymidine labelling index (TLI). The difference in response was strongly correlated to TLI. All nine responders showed an LI of 9% or greater compared with 5 of the 16 who did not respond. Furthermore, tumour regression in primary breast cancer observed after preoperative chemotherapy has been significantly associated with high S-phase fraction (O'Reilly et al., 1992; Remvikos et al., 1992; Spyratos et al., 1992) , and repeated cytological sampling during chemotherapy has indicated that tumour regression is parallelled by a decreasing growth fraction (Skoog et al., 1992) .
In levels. The same was observed if the patients were divided by tumour grade, in contrast to the study of Fisher et al. (1983) , who found that a favourable response to adjuvant therapy was more pronounced in patients with poorly differentiated tumours. Similar to the present results, however, Bonadonna et al. (1986) found that the benefit from adjuvant CMF was largely confined to patients with rapidly proliferating tumours. In both studies a strong interaction between SPF and CMF response was seen among ER-negative patients, suggesting that the mechanism of action of chemotherapy was cytotoxicity rather than chemical castration, which has been proposed as a possible mechanism in premenopausal patients. (Brincker et al., 1987) . Factors other than proliferative activity have been investigated for their possible interaction with response to chemotherapy. Gusterson et al. (1992) observed a trend towards less responsiveness in tumours overexpressing the c-erbB-2 oncogene. In studies of preoperative treatment, a more favourable response was found if the tumour was poorly differentiated, oestrogen receptor negative or DNA aneuploid (Neville et al., 1992; Spyratos et al., 1992) . These factors are known to correlate with S-phase fraction. In the series of Remvikos et al. (1989) , SPF was a better predictor of tumour responsiveness than tumour grade, hormone receptor content or DNA ploidy. In line with these results, we found that S-phase fraction correlated with response when adjusting for other variables in multivariate analysis. DNA hypodiploid tumours, which have shown to be associated with low age (Stal et al., 1992) and poor prognosis (Ferno et al., 1992) in breast cancer, also seemed to be more chemosensitive than others. A clear conclusion about an independent value cannot be made because most of the DNA hypodiploid tumours showed a high S-phase fraction.
The hypothesis that the proliferative activity of the tumour might be related to the response to chemotherapy is attractive, since most cytotoxic agents act specifically against actively DNA replicating cells. Techniques used to estimate proliferative activity are, however, associated with methodological problems. It should be noted that the investigators who found a significant relation between cell proliferation and response to treatment used either the thymidine labelling technique (Sulkes et al., 1979; Bonadonna et al., 1986) or DNA flow cytometry on fresh or frozen material (Remvikos et al., 1989; O'Reilly et al., 1992; Spyratos et al., 1992) , in contrast to others who employed paraffin-embedded fixed tissue (Hedley et al., 1987; O'Reilly et al., 1990; Witzig et al., 1993) . Irrespective of the starting material used, other problems concern intratumoral heterogeneity and errors related to the calculation model for SPF. However, although different models produce different estimated levels of SPF, we and other investigators have observed that a significant prognostic value is obtained with several models, including the manual rectangular method (Joensuu et al., 1994; Wingren et al., 1994 ). An indirect support for an interaction between SPF and response to adjuvant chemotherapy was reported from a study in which all the patients received adjuvant treatment (Kute et al., 1990) . It was found that those with a tumour of high SPF tended to have a better prognosis in contrast to the prediction of a high recurrence risk mostly found in series of systemically untreated patients.
In our study the effect of CMF was compared with that of post-operative radiotherapy in contrast to trials with adjuvant chemotherapy in which the control patients received no adjuvant treatment. Unlike the results obtained for premenopausal patients by O'Reilly et al. (1990) , we found no benefit from CMF for patients with low S-phase levels, but rather a trend towards longer distant disease-free survival in the radiotherapy group. Radiotherapy has long been regarded as locoregional treatment with little or no effect on distant recurrence or survival. However, a significant reduction in distant metastases with adjuvant radiotherapy compared with surgery alone has been observed among nodepositive patients (Auquier et al., 1992) . Although a subsequent trial has shown that the risk of distant recurrence in premenopausal patients is further reduced if radiotherapy is replaced by CMF (Rutqvist et al., 1989) , we cannot exclude the possibility of a minor benefit from chemotherapy compared with no post-operative treatment among patients whose tumours show low proliferative activity. Compared with post-operative radiotherapy, we conclude that the benefit from adjuvant chemotherapy is largely confined to patients with highly proliferative primary tumours. In this view, it is promising that a high proportion of relapses in systemically untreated premenopausal patients seems to be identified by S-phase fraction (Stal et al., 1992) . Recently, we also reported results suggesting that SPF is a long-term prognostic factor in small node-negative tumours (T1NO) (Stal et al., 1993) . These results, together with the present data, suggest that estimation of proliferative activity could facilitate the identification of early breast cancer patients suitable for adjuvant chemotherapy. This work was supported by grants from the Swedish Cancer Society.
